arrow
P

Phuoc T. Tran

the university of texas-md anderson cancer center
H指数:67
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer

不利的中危局限性前列腺癌中不一致的分子生物标志物

2026-08-250
OAAI
Twist1 overexpression models an aggressive subtype of pancreatic ductal adenocarcinoma in vivo

Twist1过表达模拟了体内胰腺导管腺癌的一种侵袭性亚型

2026-05-220
PRE
High frequency of RB1 mutations p16 positive early stage oropharyngeal carcinoma: A genomic and transcriptomic analysis

RB1基因突变在p16阳性早期口咽癌中的高频率:一项全基因组与转录组分析

2026-05-170
PRE
Re: Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski et al. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.01.008

Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski等人. 去势敏感转移性前列腺癌中无前列腺特异性抗原进展的放射学进展:ENZAMET试验(ANZUP 1304)的回顾性分析. 欧洲泌尿肿瘤学. 即将发表. http://dx.doi.org/10.1016/j.euo.2026.01.008

2026-04-110
PRE
Gallium-68-Labeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Response in Pelvic Node-Positive Prostate Cancer After Definitive Radiation Therapy: Prognostic Implications

^{68}Ga标记的前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在盆腔淋巴结阳性前列腺癌接受根治性放射治疗后的反应:预后意义

2025-10-010
PRE
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy

转移灶定向治疗的基因组预测因子:含或不含雄激素剥夺治疗

2025-09-200
PREAI
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial

持续性雄激素剥夺疗法联合或未联合转移灶定向治疗寡转移性前列腺癌:多中心II期随机EXTEND试验

2025-07-310
PRE
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial

局部高危前列腺癌的转录组学分析改善了预后判断,并确定了在NRG肿瘤学/RTOG 0521 III期试验中,将多西他赛添加到根治性放疗联合雄激素抑制治疗中获益。

2025-07-170
OAAI
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol

基于数字病理学的多模态人工智能衍生预后模型在开始长期雄激素剥夺治疗的晚期前列腺癌患者中的外部验证:STAMPEDE平台方案的四项Ⅲ期随机对照试验的回顾性附加生物标志物研究

2025-06-010
OAAI
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer
2025-01-010
PRE
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer

寡转移去势敏感性前列腺癌转移导向治疗联合或不联合雄激素阻断治疗的多机构分析

2024-12-010
OA
Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial (vol 117, pg 370, 2023)
2024-12-010
PRE